{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"* Defined as the percentage of subjects who achieve a complete response, partial response, or stable disease based on assessment of brain and systemic lesions\n* Intracranial disease: response and progression will be evaluated using the updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) working group guideline\n* Extracranial disease: response and progression will be evaluated using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)","groups":[{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG000","title":"Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG001","title":"Cohort B: Epithelial Origin Solid Tumors w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG002","title":"Cohort C: NSCLC or Non-NSCLC w/Corticosteroids"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Two participants were not evaluable in Cohort A as the extracranial response per RECIST was not done. There were not any participants enrolled in Cohort B or Cohort C.","reportingStatus":"POSTED","timeFrame":"Completion of treatment (estimated to be 6 months)","title":"Overall Disease Control Rate Considering Both Intracranial and Extracranial Disease","type":"SECONDARY","unitOfMeasure":"Participants"}